Chinook therapeutics revenue
WebChinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines ... EPS and … WebApr 14, 2024 · Chinook Therapeutics had a negative return on equity of 40.61% and a negative net margin of 3,065.68%. The firm’s revenue was down 90.0% on a year-over-year basis. As a group, analysts predict that Chinook Therapeutics, Inc. will post -3.19 earnings per share for the current year. Insider Activity
Chinook therapeutics revenue
Did you know?
WebChinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SEATTLE, March 03, 2024 (GLOBE NEWSWIRE) -- Chinook … WebChinook Therapeutics revenue from 2014 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of …
WebApr 9, 2024 · Chinook Therapeutics Trading Down 0.8 %. Shares of KDNY opened at $22.12 on Friday. The firm’s 50-day moving average is $23.02 and its two-hundred day moving average is $22.82. WebNov 8, 2024 · Chinook (KDNY) delivered earnings and revenue surprises of 17.07% and -98.40%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
WebMar 25, 2024 · This is a summary of current ratings and price targets for Bio-Path and Chinook Therapeutics, as provided by MarketBeat. Bio-Path presently has a consensus price target of $9.00, indicating a ... WebApr 14, 2024 · The firm had revenue of $5.10 million during the quarter, compared to analyst estimates of $0.10 million. Chinook Therapeutics’s revenue was down 90.0% on a year-over-year basis. As a group, equities analysts forecast that Chinook Therapeutics will post -3.19 earnings per share for the current fiscal year. Insider Activity at Chinook …
WebFeb 24, 2024 · Chinook Therapeutics is a biotechnology company developing precision medicines for kidney diseases. The company applies its proprietary discovery platform, … optics questions and answersWebApr 6, 2024 · 9 brokers have issued 1 year price objectives for Chinook Therapeutics' shares. Their KDNY share price forecasts range from $30.00 to $44.00. On average, they predict the company's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 64.1% from the stock's current price. optics ray tracing softwareWebChinook Therapeutics Revenue is currently at 51.62 K. Revenue is income that a firm generates from business activities such us rendering services or selling goods to … portland maine channel 8 weatherWebSep 30, 2024 · SEATTLE, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the third quarter ended September 30, … portland maine charter commission resultsWebNov 10, 2024 · Chinook Therapeutics (KDNY) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.68 per share a year ago. optics rated for 300blkWebAug 8, 2024 · Revenue – Revenue for the quarter and six months ended June 30, 2024 was $0.4 million and $3.1 million, respectively, compared to less than $0.1 million and $0.4 million for the same periods in ... optics ray diagram infinity corrected lensesWebApr 11, 2024 · Chinook Therapeutics, Inc. SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and ... optics ray diagrams